In a first, combining AstraZeneca vaccine and Sputnik V shows 'no serious adverse effects': RDIF
By Team Newsable | First Published Jul 30, 2021, 7:06 PM ISTIn a statement, RDIF's CEO Dmitriev said as a part of technology transfer, SII has already received cell and vector samples from the Gamaleya Center. He also said that their import is approved by the Drug Controller General of India.
The Russian Direct Investment Fund (RDIF) on Friday announced that there were no serious side effects with the combination between the AstraZeneca vaccine and the first component of the Sputnik V vaccine among the volunteers. The trial involved 50 people and began in Azerbaijan in February.
In a statement, RDIF's CEO Dmitriev said as a part of technology transfer, SII has already received cell and vector samples from the Gamaleya Center. He also said that their import is approved by the Drug Controller General of India.
Latest Videos
Speaking on the agreement with SII, Dmitriev added that the agency is delighted to cooperate with the world's largest vaccine manufacturer.
He said that this partnership is a major step to substantially increase our production capabilities, demonstrating a perfect example of joining forces and expertise to save lives.
Earlier, RDIF had agreements with a number of pharmaceutical companies in India for the production of the vaccine. At present, the Sputnik V vaccine has registered in 67 countries globally, with a total population of over 3.5 billion people.
RDIF, Russia’s sovereign wealth fund, and SII have also announced cooperation to produce the Russian Sputnik vaccine against coronavirus in India. The first batch of the vaccines is expected to be produced at SII’s facilities in September, and both parties intend to produce over 300 million doses of the vaccine in India per year.
subscribe to Asianet Newsable WhatsApp channel by clicking here.